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Abstract
Background: Dyslipidemia in pregnancy are associated with gestational diabetes mellitus (GDM), preeclampsia,
preterm birth and other adverse outcomes, which has been extensively studied in western countries. However,
similar studies have rarely been conducted in Asian countries. Our study was aimed at investigating the associations
between maternal dyslipidemia and adverse pregnancy outcomes among Chinese population.
Methods: Data were derived from 934 pairs of non-diabetic mothers and neonates between 2010 and 2011. Serum
blood samples were assayed for fasting total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol
(HDL-C), and low-density lipoprotein-cholesterol (LDL-C) concentrations during the first, second and third trimesters.
The present study explored the associations between maternal lipid profile and pregnancy complications and
perinatal outcomes. The pregnancy complications included GDM, preeclampsia and intrahepatic cholestasis of
pregnancy (ICP); the perinatal outcomes included preterm birth, small/large for gestational age (SGA/LGA) infants
and macrosomia. Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were calculated and adjusted via
stepwise logistic regression analysis. Optimal cut-off points were determined by ROC curve analysis.
Results: After adjustments for confounders, every unit elevation in third-trimester TG concentration was
associated with increased risk for GDM (OR = 1.37, 95 % CI: 1.18-1.58), preeclampsia (OR = 1.50, 95 % CI: 1.16-1.93),
ICP (OR = 1.28, 95 % CI: 1.09-1.51), LGA (OR = 1.13, 95 % CI: 1.02-1.26), macrosomia (OR = 1.19, 95 % CI: 1.02-1.39)
and decreased risk for SGA (OR = 0.63, 95 % CI: 0.40-0.99); every unit increase in HDL-C concentration was
associated with decreased risk for GDM and macrosomia, especially during the second trimester (GDM: OR = 0.10,
95 % CI: 0.03-0.31; macrosomia: OR = 0.25, 95 % CI: 0.09-0.73). The optimal cut-off points for third-trimester TG
predicting GDM, preeclampsia, ICP, LGA and SGA were separately ≥3.871, 3.528, 3.177, 3.534 and ≤2.530 mmol/L.
The optimal cut-off points for third-trimester HDL-C identifying GDM, macrosomia and SGA were respectively
≤1.712, 1.817 and ≥2.238 mmol/L.
Conclusions: Among Chinese population, maternal high TG in late pregnancy was independently associated
with increased risk of GDM, preeclampsia, ICP, LGA, macrosomia and decreased risk of SGA. Relative low maternal
HDL-C during pregnancy was significantly associated with increased risk of GDM and macrosomia; whereas
relative high HDL-C was a protective factor for both of them.
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Background
Evidence has suggested that adverse pregnancy outcomes
can jeopardize short- and long-term maternal and fetal
health. Women with previous gestational diabetes mellitus
(GDM) have an increased risk of type 2 diabetes or cardio-
vascular diseases (CVD) in later life [1, 2]. Pregnancies
accompanied with preeclampsia have the predisposition to
future CVD and metabolic syndrome [3–5]. According to
Developmental origins of Health and Disease (DOHaD)
hypothesis, individuals who were exposed to an under-
nourished intrauterine environment are more prone to
developing type 2 diabetes or CVD in later life as a result
of epigenetic modifications, which permanently repro-
gramme their bodies [6, 7]. Therefore, it is of great im-
portance to explore effective interventions to prevent
these adverse outcomes. It is noteworthy that disturbed
maternal metabolism, including atherogenic lipid changes
in pregnancy, is one of the crucial factors that involved in
pathological process.
From the 12th week of pregnancy, lipid parameters,
including total cholesterol (TC), triglycerides (TG),
low-density lipoprotein-cholesterol (LDL-C), high-
density lipoprotein-cholesterol (HDL-C) and phospho-
lipid gradually increase, especially in the second and
third trimesters [8–13]. Previous research has indicated
that pregnancy-induced hyperlipidemia contributes to
an increased morbidity of GDM and preeclampsia. At
all gestational stages, high TG concentrations were
associated with a raised risk for gestational impaired
glucose tolerance (GIGT) and GDM [14–16]. Results of a
few studies have suggested a concentration-dependent
positive association between maternal TG and the risk
for preeclampsia [17–20]. Moreover, evidence has
shown pregnant women with higher oxidized LDL-C
concentrations are also at greater risk of developing
preeclampsia [21–23]. In addition, Amsterdam Born
Children and Their Development cohort study discovered
that maternal TG concentrations in early pregnancy were
linearly related with the prevalence of pregnancy-induced
hypertension, preeclampsia, induced preterm birth (PTB)
and large for gestational age (LGA) [24].
Except for pregnancy complications, maternal dyslipid-
emia is also closely linked with adverse perinatal out-
comes. Catov et al. [25] reported that both elevated
cholesterol and TG in early pregnancy were associated
with an increased risk of spontaneous PTB. Furthermore,
maternal impaired TG and non-esterified fatty acids
(NEFA) metabolism were correlated with excessive fetal
growth [26, 27]. In women diagnosed with GDM, it has
been demonstrated that maternal TG and NEFA concen-
trations in late pregnancy are positively correlated with
newborns’ birth weight, body mass index (BMI) and fat
mass [28–30]. Interestingly, other clinical trials have indi-
cated maternal fasting TG is positively correlated with
neonatal body weight even in women with normal glu-
cose tolerance but positive diabetic screenings [31, 32].
Additionally, recent studies have described a positive
association between maternal TG concentrations and
the risk for LGA newborns independent of glycemic
control [24, 31, 33].
Despite these findings, there are still some controver-
sies on the relationship between maternal lipid distur-
bances and certain pregnancy complications or perinatal
outcomes. For instance, GDM was discovered to be
associated with lower maternal LDL-C and HDL-C
concentrations during the second and third trimesters in
several studies [15, 34–36]. Nevertheless, other assays
showed no significant difference in the concentrations of
LDL-C and HDL-C between GDM and normal pregnan-
cies [34, 36–38]. Additionally, as mentioned before, there
exists a debate focused on whether maternal TG is posi-
tively correlated with neonatal birth weight only in GDM/
diabetic subjects or also in nondiabetic ones [28–33, 39].
These conflicting results could potentially be explained by
differences in trimester of pregnancy, condition of gly-
cemic control, race/ethnicity and sample size, but the real
causes remain unknown.
Our study was aimed at comprehensively investigating
the associations between Chinese maternal lipid profile
and adverse pregnancy outcomes, i.e. GDM, preeclampsia,
intrahepatic cholestasis of pregnancy (ICP), PTB, LGA,
small for gestational age (SGA) and macrosomia. At the
same time, we attempted to advance understandings and




Between 30 June 2010 and 30 June 2011, pregnant
women who attended regular prenatal health care and
intended to give a birth in Women’s Hospital, Zhejiang
University School of Medicine were invited to participate
in the study. Before enrollment, our study was approved
by the hospital’s Clinical Research Ethics Committee and
written informed consent was signed by every partici-
pant. We established the study cohort based on inclu-
sion and exclusion criteria. Inclusion criteria of pregnant
women were: 1) pregnant at 28–37 gestational weeks; 2)
had integrated medical records and clear gestational age;
3) singleton pregnancy; and 4) naturally conceived.
Exclusion criteria of pregnant women were: 1) multiple
pregnancy; 2) had diabetes mellitus, chromosomal abnor-
malities, inherited metabolic diseases or thyroid diseases
before pregnancy; 3) experienced serious infection during
early pregnancy; and 4) conceived with assisted reproduct-
ive techniques. A total of 1020 expectant mothers were
recruited. All the women included were requested to
complete an extensive questionnaire about maternal age,
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height, parity, prepregnancy weight, gestational weight
gain (GWG), lifestyle, education background, family in-
come and other important information. Data on first-
trimester and second-trimester lipid concentrations,
GDM, preeclampsia and ICP were collected from med-
ical records. They were followed from recruitment to
delivery. Information on delivery mode, gestational age,
newborn sex, birth weight, Apgar scores and perinatal
outcomes were recorded by midwives or obstetricians
upon delivery. Inclusion criteria for newborns were single-
ton and 5-min-postpartum Apgar scores ≥ 7. Exclusion
criteria for newborns were chromosomal abnormalities,
inherited metabolic diseases and congenital abnormalities.
Finally, 934 pairs of mothers and neonates were eligible
for our study.
Biochemical analyses
Venous blood samples were taken after overnight fast-
ing from all the participants at the first (7–10 gesta-
tional weeks), second (21–24 gestational weeks) and
third (33–37 gestational weeks) trimester of pregnancy.
The blood samples were collected in a 3.5-ml vacutai-
ner (BD Plymouth, PL6 7BP, UK, SST II Advance
Tubes) for the preparation of serum. At the biochem-
ical laboratory of Women’s Hospital, Zhejiang Univer-
sity School of Medicine, 1-ml aliquots of serum
samples were obtained by centrifugation (3500 rpm for
10 min at 4 °C) and stored at −20 °C until analysis.
Every sample was assayed for TC, TG, HDL-C and
LDL-C concentrations. TC was assayed with the choles-
terol oxidase-phenol aminophenazone method and TG
was assayed using the glycerol-3-phosphatase oxidase-
phenol aminophenazone method. HDL-C and LDL-C
were measured by homogeneous enzymatic colorimet-
ric assays. All the lipid measurements were performed
on an automatic biochemical analyser (Abbott Archi-
tect C16000, Abbott Laboratories, USA) respectively
with TC, TG, HDL-C and LDL-C detection kits (Abbott
Diagnostic Kit, Abbott Laboratories, USA). The inter-
and intra-assay coefficients of variation were <1.9 %,
0.81 % (TC); <1.9 %, 1.6 % (TG); <1.0 %, 0.44 % (HDL-
C) and <1.9 %, 1.5 % (LDL-C), respectively.
Definitions
BMI was calculated by dividing weight in kilograms by the
square of height in meters. Maternal prepregnancy BMI
was categorized into underweight (<18.5 kg/m2), normal
weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2),
and obese (≥30.0 kg/m2) groups on the basis of World
Health Organization BMI classification [40]. According to
the new recommendations from American Institute of
Medicine, GWG was stratified into appropriate, inad-
equate and excessive groups [41]. Based on different
prepregnancy BMIs, appropriate GWG was defined as
12.5-18.0 kg in underweight women, 11.5-16.0 kg in nor-
mal weight women, 7.0-11.5 kg in overweight women and
5.0-9.0 kg in obese women. Exceeding the thresholds was
defined as excessive GWG, while falling below the thresh-
olds was defined as inadequate GWG.
GDM was diagnosed according to the recommenda-
tions from International Association of Diabetes and
Pregnancy Study Groups [42, 43]. The proposed criteria
for GDM were as follows: Before an oral glucose toler-
ance test (OGTT), every participant was requested for a
50 g glucose challenge test and serum glucose levels
were assayed 1 hr later. Subjects with positive results
(glucose levels ≥7.8 mmol/L) were required to undergo a
75 g OGTT. Serum glucose levels during OGTT were
measured at 0, 1 and 2 hr, respectively. The normal
values were fasting glucose <5.1 mmol/L, 1-hr glucose
<10.0 mmol/L and 2-hr glucose <8.5 mmol/L. If one or
more values equaled or exceeded the above thresholds,
women were diagnosed as having GDM.
Hypertensive disorders in pregnancy were a set of
diseases including pregnancy-induced hypertension, pre-
eclampsia, eclampsia, chronic hypertension complicating
pregnancy and preeclampsia superimposed upon chronic
hypertension. Preeclampsia was defined as a specific
pregnancy-induced disorder characterized with hyper-
tension (systolic blood pressure ≥140 mmHg and/or
diastolic blood pressure ≥90 mmHg) and significant
proteinuria (urine protein ≥300 mg/24 h or positive re-
sults in random urine protein tests) in previously
normotensive women on or after 20 weeks gestational
age [44].
ICP is a pregnancy-specific disorder typically occurs in
the third trimester characterized by pruritus and jaun-
dice. Confirmation of diagnosis relied on abnormal liver
function tests and raised maternal serum bile acids [45].
Abnormal liver function tests included elevated levels
of alanine aminotransferase, aspartate aminotransferase
and/or gamma-glutamyl transpeptidase. The upper
limits of total serum bile acids were 10–14 micromoles/
L in postprandial state and 6–10 micromoles/L in fast-
ing state. Exceeding the upper limits was an important
diagnostic basis of ICP.
Preterm birth was defined as birth of newborns less than
37 weeks gestational age. Newborns were classified into
appropriate for gestational age (AGA), SGA and LGA on
the basis of Neonatal Birth Weight for Gestational Age
and Percentile in 15 Cities of China [46]. Neonates were
defined as SGA if their birth weights fell below the 10th
percentile for gestational age and as LGA if their birth
weights exceeded the 90th percentile for gestational age.
AGA was defined as birth weights met or exceeded the
10th percentile and met or fell below the 90th percentile
for gestational age. According to the birth weight, neo-
nates could be stratified into low birth weight (<2500 g),
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normal birth weight (2500–4000 g) and macrosomia
(>4000 g) groups.
Statistical analysis
In our study, normally and non-normally distributed
continuous variables were respectively presented as
mean ± standard deviation (SD) and median (interquar-
tile range, IQR), categorical variables were presented as
N (%). Serum TC, TG, LDL-C, HDL-C concentrations
at the first, second and third trimesters were compared
by Kruskal-Wallis test. Maternal lipid increases from
the first to second trimester and the second to third
trimester were compared using Mann–Whitney test.
Forward stepwise logistic regression analysis were ap-
plied to explore the associations between maternal dys-
lipidemia and pregnancy complications and perinatal
outcomes. We considered GDM, preeclampsia and ICP
as pregnancy complications; and PTB, SGA, LGA,
macrosomia as perinatal outcomes. In the multivariable
adjusted model, maternal age, prepregnancy BMI, GWG,
parity, cigarette exposure, socioeconomic status, infant
sex and delivery mode were regarded as confounding vari-
ables. ROC curve analysis was conducted to determine
the optimal cut-off points of TG, HDL-C and LDL-C for
predicting maternal and neonatal adverse outcomes. Each
optimal cut-off point was assessed via searching for the
maximum value of sensitivity + specificity–1 (Youden
index). Area under curve (AUC) was calculated to evalu-
ate the predictive powers. All the analyses were performed
with SPSS version 19.0 for Windows (SPSS Inc, Chicago,
III, USA). P values < 0.05 were defined as statistically
significant.
Results
Maternal lipid profile by trimester
Table 1 shows maternal lipid profile by trimester. Serum
TC, TG, LDL-C, HDL-C concentrations increased as
pregnancy advanced. All the lipid parameters of the
third trimester were higher than those of the first and
second trimesters (p < 0.001). Furthermore, the increases
in lipid concentrations from the second to third trimes-
ter were larger than those from the first to second tri-
mester (p < 0.001). From the second to third trimester,
TC, TG, LDL-C and HDL-C concentrations increased by
35.5 %, 24.1 %, 13.4 % and 9.0 %, respectively. In con-
trast, the data was separately 12.9 % (TC), 12.3 % (TG),
10.2 % (LDL-C), 4.8 % (HDL-C) from the first to second
trimester.
Characteristics of study population
Table 2 presents maternal and neonatal characteristics of
our study population. Among the 934 eligible mothers in
the present study, the mean (SD) age at delivery was 29.21
(3.76) years old. Approximately 83 % of them were nul-
liparous and about 7 % of them were stratified as over-
weight or obese with prepregnancy BMI ≥ 25.0 kg/m2.
Their mean (SD) prepregnancy BMI was 20.66 (2.70) kg/
m2. The prevalence of maternal comorbidities, including
GDM, preeclampsia and ICP was respectively 7.6 %, 1.5 %
and 6.3 %. The mean (SD) gestational weight gain was
15.27 (4.00) kg. According to the IOM recommendations
for gestational weight gain, 54.0 % met, 15.4 % fell below
and 30.6 % exceeded the criteria. The newborns in our
study had a mean (SD) birth weight of 3396.41 (436.52) g.
71.3 % of them were AGA, 2.4 % were SGA and 26.3 %
were LGA. 1.3 % of them belonged to low birth weight
group and 8.0 % belonged to macrosomia group. The
mean (SD) gestational age at birth was 38.84 (1.22) weeks.
Associations between maternal lipid profile and
pregnancy complications and perinatal outcomes
Table 3 displays the associations between maternal
third-trimester lipid profile and pregnancy complications
and perinatal outcomes. Of all the expectant mothers,
7.6 % developed GDM, 1.5 % preeclampsia and 6.3 %
ICP. We observed every mmol/L elevation in maternal
third-trimester TG concentration was associated with an
increased risk of GDM [p < 0.001, adjusted odds ratio
(AOR) = 1.37, 95 % confidence interval (CI): 1.18-1.58],
preeclampsia (p = 0.002, AOR = 1.50, 95 % CI: 1.16-1.93)
and ICP (p = 0.002, AOR = 1.28, 95 % CI: 1.09-1.51). In
addition, every unit increase in LDL-C reduced the risk
of GDM (p < 0.001, AOR = 0.52, 95 % CI: 0.38-0.72).
While on the other hand, there were no significant asso-
ciations between TC concentrations and all the above
pregnancy complications.
Table 1 Maternal lipid profile by trimester
Lipids First Second Third First-Second Second-Third p* p**
TC 3.95 (3.66-4.60) 4.65 (4.22-5.10) 6.27 (5.52-7.03) 0.51 (0.21-0.87) 1.65 (1.04-2.29) 0.000 0.000
TG 2.20 (1.77-2.73) 2.45 (2.11-2.89) 3.06 (2.37-3.98) 0.27 (0.09-0.51) 0.59 (0.12-1.11) 0.000 0.000
LDL-C 2.25 (2.08-2.45) 2.46 (2.22-2.77) 2.87 (2.32-3.45) 0.23 (0.03-0.46) 0.33 (−0.09-0.84) 0.000 0.000
HDL-C 1.66 (1.45-1.77) 1.67 (1.47-1.79) 1.80 (1.57-2.04) 0.08 (−0.12-0.21) 0.15 (−0.09-0.32) 0.000 0.000
TC total cholesterol, TG triglycerides, LDL-C/HDL-C low-density/high density lipoprotein-cholesterol
Maternal lipid concentrations and increases were presented as median (IQR) mmol/L
*p values were derived from the comparisons among lipid concentrations of the first, second, and third trimesters
**p value were derived from the comparisons between lipid increases from the first to second trimester and the second to third trimester
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In our study, the incidence of PTB, SGA, LGA and
macrosomia was 2.9 %, 2.4 %, 26.3 % and 8.0 %, respect-
ively. Table 3 showed there was no significant association
between third-trimester TG and PTB. However, multivari-
ate analysis discovered that every mmol/L increase in
third-trimester TG concentration was associated with an
increased risk for LGA (p = 0.025, AOR = 1.13, 95 % CI:
1.02-1.26) and macrosomia (p = 0.024, AOR = 1.19,
95 % CI: 1.02-1.39), a decreased risk for SGA (p =
0.046, AOR = 0.63, 95 % CI: 0.40-0.99). In contrast,
there were no significant associations between TC and
LDL-C concentrations and all the above perinatal
outcomes.
Table 4 reports the associations between maternal
HDL-C concentrations and GDM, macrosomia and SGA
at all gestational stages. Significant negative associations
were observed between HDL-C and the risk for GDM
(during the whole pregnancy) and macrosomia (during
the second and third trimesters). The strongest inverse
associations appeared during the second trimester.
Every unit increase in second-trimester HDL-C concen-
tration was associated with a decreased risk for GDM
(p < 0.001, AOR = 0.10, 95 % CI: 0.03-0.31) and macroso-
mia (p = 0.011, AOR = 0.25, 95 % CI: 0.09-0.73). Addition-
ally, women with higher HDL-C concentrations were at a
greater risk of having SGA offsprings and the relationship
reached statistical significance at the third trimester
(p = 0.026, AOR = 3.15, 95 % CI: 1.15-8.65).
Table 5 presents the optimal cut-off points of maternal
third-trimester lipids for predicting pregnancy complica-
tions and perinatal outcomes. The optimal cut-off points
proposed by ROC curve analysis for third-trimester TG in
predicting GDM, preeclampsia, ICP, LGA and SGA were
separately ≥3.871, 3.528, 3.177, 3.534 and ≤2.530 mmol/L.
TG predicting preeclampsia owned the strongest predict-
ive power with the largest AUC [0.736 (95 % CI: 0.595-
0.876)]. The optimal cut-off points for third-trimester
HDL-C in identifying GDM, macrosomia and SGA were
respectively ≤1.712, 1.817 and ≥2.238 mmol/L. HDL-C
identifying GDM had the strongest predictive ability with
the largest AUC [0.617 (95 % CI: 0.548-0.686)]. Besides,
the optimal cut-off point for third-trimester LDL-C in
predicting GDM was ≤2.415 mmol/L.
Except for the last trimester, per unit elevation in TG
concentrations could led to 1.58-fold increased risk of
Table 2 Maternal and neonatal characteristics
Characteristics Mean ± SD or N (%)
Maternal characteristics




Prepregnancy BMI (kg/m2) 20.66 ± 2.70
Underweight (<18.5) 192 (20.7)
Normal weight (18.5-24.9) 669 (72.1)
Overweight and obese (≥25.0) 67 (7.2)






Junior college 296 (31.7)
High school 36 (3.9)
















Vaginal delivery 216 (23.1)
Cesarean section 718 (76.9)
Neonatal characteristics
Male infant 493 (52.8)
Gestational age (GA) at delivery 38.84 ± 1.22
Preterm (GA < 37 weeks) 27 (2.9)
Full term (37≤ GA < 42 weeks) 907 (97.1)




Table 2 Maternal and neonatal characteristics (Continued)




BMI body mass index, GDM gestational diabetes mellitus, ICP intrahepatic
cholestasis of pregnancy, SGA/AGA/LGA small/appropriate/large for
gestational age
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GDM in the first trimester (p = 0.003, AOR = 1.58, 95 %
CI: 1.17-2.15) and 1.55-fold increased risk in the second
trimester (p = 0.001, AOR = 1.55, 95 % CI: 1.19-2.02).
Moreover, high TG at the second trimester were signifi-
cantly associated with the morbidity of ICP (p = 0.006,
AOR = 1.50, 95 % CI: 1.12-2.00). Pregnant women with
higher LDL-C during the second trimester were at re-
duced risk of GDM (p = 0.010, AOR = 0.48, 95 % CI:
0.28-0.84).
Discussion
In this population-based study, we comprehensively
displayed maternal fasting lipid profile by trimester in
Chinese reproductive-age women and explored the as-
sociations between maternal lipid concentrations and
pregnancy complications and perinatal outcomes. The
present study confirmed maternal TG concentrations
in pregnancy were positively associated with the risk of
GDM, preeclampsia, LGA and macrosomia among
Chinese population, which was in line with previous re-
search performed in other races/ethnicities [14–20, 24,
31]. Furthermore, we found maternal high HDL-C
concentrations were significantly associated with a de-
creased risk for GDM and macrosomia, and an increased
risk for SGA. At the same time, hypertriglyceridemia dur-
ing pregnancy was a significant predictor of ICP. These
were the main novel discoveries in our study, suggesting
complex metabolic disorders of maternal lipids were
potentially important factors that involved in the patho-
logical processes of adverse pregnancy outcomes.
One striking finding from this study was that maternal
HDL-C concentrations were negatively associated with
the risk for GDM and macrosomia, and positively asso-
ciated with the risk for SGA. These associations indi-
cated maternal HDL-C concentrations beyond a certain
range was an underlying predictor of GDM, macrosomia
or SGA. Very few relevant reports could be found in the
past [34, 47, 48]. Among them, Wang et al. [47] believed
insulin resistance, relative lack of insulin secretion and
oxidative stress were the main contributors of maternal
hypertriglyceridemia and low HDL-C concentrations, es-
pecially in GDM pregnancies.
Another interesting finding was that maternal high
TG concentrations during the second and third trimes-
ters were associated with an increased risk of ICP. This
phenomenon has rarely been reported in the prior
studies as far as we know. Evidence from a recent pro-
spective study suggested that ICP was related with
higher TG concentrations and lower HDL-C concentra-
tions under fasting conditions [49]. Currently, theoret-
ical explanations provided by Fiorucci et al. [50] and
Sharma et al. [51] implied reduction in the activity of
Table 3 Associations between maternal third-trimester lipid profile and pregnancy complications and perinatal outcomes
TC TG LDL-C HDL-C
Outcomes AOR (95%CI) p value AOR (95%CI) p value AOR (95%CI) p value AOR (95%CI) p value
GDM 0.84 (0.68-1.04) 0.109 1.37 (1.18-1.58) 0.000 0.52 (0.38-0.72) 0.000 0.27 (0.13-0.58) 0.001
Preeclampsia 0.99 (0.64-1.54) 0.979 1.50 (1.16-1.93) 0.002 0.65 (0.33-1.31) 0.228 0.48 (0.10-2.26) 0.352
ICP 1.20 (0.97-1.49) 0.096 1.28 (1.09-1.51) 0.002 1.29 (0.94-1.76) 0.113 0.56 (0.25-1.22) 0.141
PTB 0.80 (0.57-1.11) 0.180 1.04 (0.77-1.38) 0.818 0.83 (0.52-1.32) 0.430 1.05 (0.37-3.00) 0.931
SGA 1.12 (0.80-1.56) 0.520 0.63 (0.40-0.99) 0.046 1.16 (0.71-1.89) 0.565 3.15 (1.15-8.65) 0.026
LGA 0.98 (0.86-1.11) 0.715 1.13 (1.02-1.26) 0.025 0.93 (0.78-1.11) 0.418 0.79 (0.52-1.21) 0.281
Macrosomia 0.99 (0.81-1.21) 0.903 1.19 (1.02-1.39) 0.024 0.93 (0.69-1.25) 0.621 0.46 (0.22-0.94) 0.034
AOR adjusted odds ratio, CI confidence interval, GDM gestational diabetes mellitus, ICP intrahepatic cholestasis of pregnancy, PTB preterm birth, SGA/LGA small/
large for gestational age, TC total cholesterol, TG triglycerides, LDL-C/HDL-C low-density/high-density lipoprotein-cholesterol
Odds ratios were adjusted for maternal age, prepregnancy BMI, gestational weight gain, parity, maternal education background, family income and cigarette
exposure. Values of PTB, SGA, LGA and macrosomia were additionally corrected for delivery mode and infant sex
Table 4 Associations between maternal HDL-C and GDM, macrosomia and SGA
GDM Macrosomia SGA
Trimester AOR (95%CI) p value AOR (95%CI) p value AOR (95%CI) p value
First 0.15 (0.05-0.42) 0.000 0.51 (0.19-1.36) 0.178 1.31 (0.32-5.38) 0.709
Second 0.10 (0.03-0.31) 0.000 0.25 (0.09-0.73) 0.011 1.88 (0.47-7.59) 0.377
Third 0.27 (0.13-0.58) 0.001 0.46 (0.22-0.94) 0.034 3.15 (1.15-8.65) 0.026
AOR adjusted odds ratio, CI confidence interval, GDM gestational diabetes mellitus, SGA small for gestational age, HDL-C high-density lipoprotein-cholesterol
Odds ratios were adjusted for maternal age, prepregnancy BMI, gestational weight gain, parity, maternal education background, family income and cigarette
exposure. Values of macrosomia and SGA were additionally corrected for delivery mode and infant sex
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bile acid receptors FXR and TGR5 may be responsible
for the above conclusion, however, the potential mecha-
nisms still deserve further exploration.
Our study advanced the understandings of previous
controversies and helped to elucidate these issues. One
dispute was concerned with LDL-C concentrations in
GDM pregnant women. In past studies, certain re-
searchers observed a tendency of lower LDL-C concen-
trations in expectant mothers with GDM and some of
them even discovered atherogenic alterations in LDL
particles (increased small size, dense LDL particles and
raised LDL susceptibility to oxidation) [16, 35, 38]. But
there were contradictory reports stating no significant
difference of LDL-C concentrations between diabetic
and nondiabetic pregnancies [34, 37]. For this argument,
our results supported an inverse association between
LDL-C concentrations and the prevalence odds of GDM,
especially during the second and third trimesters. In our
opinion, the conflicting consequences implied maternal
lipid concentrations were influenced by complicated fac-
tors (e.g. condition of glycemic control, trimester of
pregnancy and race/ethnicity).
There exists another debate focused on the correla-
tions between maternal TG concentrations and neonatal
body measurements. It has been demonstrated in some
publications that maternal TG concentrations were posi-
tively correlated with neonatal birth weight or fat mass
in pregnancies complicated by GDM or diabetes [28–30,
33, 39]; whereas in other articles TG concentrations
were positively related with fetal development in subjects
with normal glucose tolerance [31, 32]. Interestingly,
many scholars once hypothesized that excessive fetal
growth is derived from GDM or GIGT themselves. That
means the aforementioned positive correlation may be
interfered by maternal glycemic conditions. Recently,
more and more studies verified the hypothesis, suggest-
ing GDM was an independent risk factor for macroso-
mia [52, 53]. Consequently, our results emphasized
maternal TG concentrations were independently and
positively correlated with neonatal birth weight, in
accordance with the viewpoints of Amsterdam Born
Children and their Development cohort study [24, 54].
Compared with the existing findings, there was an in-
consistent outcome in our study. In contrast with pre-
vious studies [24, 25], no significant associations were
observed between maternal TG concentrations and the
occurrence of PTB according to our results, whatever
the gestational stage was. From our perspective, the
conflicting outcomes may be explained by racial/ethni-
cal differences, which means fetuses in different ethnic
groups are disproportionally affected by maternal lipid
metabolism. Future parallel studies are required to ex-
plore the underlying mechanisms of this discrepancy.
Our study has several attractive strengths. It provided
some prospective evidence suggesting that dislipidemia
during pregnancy places Chinese expectant mothers and
their offspring at greater risk of adverse outcomes.
Although lipid metabolism in pregnancy has been ex-
plored, there are controversies regarding its associations
with pregnancy complications and fetal development. To
our knowledge, few studies have investigated the relation-
ship in Asian countries, particularly in China. Compared
with the study conducted by Wang et al. [47] which
assessed the associations between TG/HDL-C ratios and
the risk of GDM and LGA, we separately identified the
contributions of TG and HDL-C to pregnancy outcomes
and expanded insights into effects of different lipid com-
ponents on mothers and neonates. Indeed, a majority of
Table 5 Optimal cut-off points of maternal third-trimester lipids for predicting pregnancy complications and perinatal outcomes
Outcomes AUC (95 % CI) Sensitivity (%) Specificity (%) Youden index Cut-off point (mmol/L)
TG
GDM 0.633 (0.566-0.701) 47.9 74.2 0.221 3.871
Preeclampsia 0.736 (0.595-0.876) 85.7 64.8 0.505 3.528
ICP 0.607 (0.528-0.685) 66.1 55.9 0.220 3.177
LGA 0.571 (0.529-0.613) 44.7 67.4 0.121 3.534
SGA 0.658 (0.540-0.775) 63.6 68.9 0.325 2.530
HDL-C
GDM 0.617 (0.548-0.686) 57.7 61.2 0.189 1.712
Macrosomia 0.592 (0.527-0.657) 66.7 49.8 0.165 1.817
SGA 0.606 (0.457-0.756) 40.9 88.7 0.296 2.238
LDL-C
GDM 0.649 (0.582-0.715) 54.9 71.7 0.266 2.415
AUC area under curve, CI confidence interval, GDM gestational diabetes mellitus, ICP intrahepatic cholestasis of pregnancy, SGA/LGA small/large for gestational
age, TG triglycerides, HDL-C/LDL-C high-density/low-density lipoprotein-cholesterol
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existing trials focused on the concentrations of TG, TC,
LDL-C and their influences on maternal and perinatal
outcomes, however, less attention had been paid to HDL-
C. Our study not only described the variation trend of
HDL-C concentrations by trimester, but also evaluated its
role in developing GDM, macrosomia and SGA. More-
over, we proposed the optimal cut-off points of maternal
third-trimester lipids in predicting adverse pregnancy out-
comes, which was a new contribution has rarely appeared
in previous research.
However, the present study still has some limitations.
First of all, our sample lacked population diversity. Given
that China is a country characterized by huge population
and imbalanced regional economic development, a mul-
ticenter study with larger sample size can be more repre-
sentative. Secondly, we selected Neonatal Birth Weight
for Gestational Age and Percentile in 15 Cities of China
as the criteria for LGA and SGA infants in our analysis.
Defect of this criteria is its applicability worths further
discussion with the increasing Chinese neonatal birth
weights. Thirdly, some collected data of maternal charac-
teristics (e.g. prepregnancy weight and GWG) were self-
reported and possibly be subject to recall bias. Finally, we
cannot rule out the possibility of residual confounding.
For example, excessive dietary nutrition intake and inad-
equate physical activity during pregnancy may be import-
ant contributors of dyslipidemia, but we failed to include
sufficient information on dietary nutrition intake and
physical activity. Thus, additional studies are needed to
clarify the relationship between maternal lifestyle and dys-
lipidemia and pregnancy outcomes.
Conclusions
Our results suggested that maternal high TG concen-
trations in late pregnancy were independently and sig-
nificantly associated with an increased risk of GDM,
preeclampsia, ICP, LGA, macrosomia and a decreased
risk of SGA among Chinese population. Additionally,
relative low HDL-C during pregnancy was significantly
related with the occurence of GDM and macrosomia;
whereas relative high HDL-C was a protective factor
for both of them. Our findings highlighted the import-
ance of maternal lipid metabolism in preventing preg-
nancy complications and adverse birth outcomes.
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